Burden of HPV Related Anogenital Diseases in Young Women in Germany – An Analysis of German Statutory Health Insurance Claims Data From 2012–2017

Miriam Reuschenbach

Sarah Mihm

MSD SHARP & DOHME GmbH

Regine Wölle

MSD SHARP & DOHME GmbH

Kim Maren Schneider

Xcenda GmbH

Christian Jacob

Xcenda GmbH

Sebastian Braun

Xcenda GmbH

Wolfgang Greiner

Bielefeld University

Monika Hampl

Department of Obstetrics abd Gynecology, University Hospital of Duesseldorf

Research article

Keywords: Human papillomavirus (HPV), Genital warts, Cervical intraepithelial neoplasia, Prevalence, Claims data, Statutory health insurance, Germany

Abstract

Background

Most women and men will be infected with human papillomavirus (HPV) at least once in their lifetime. Infections with low-risk types can cause genital warts, whereas high-risk types can cause malignant tumors. The aim of this study was to determine the burden of anogenital diseases potentially related to HPV in young women based on German statutory health insurance claims data.

Methods

We conducted a retrospective claims data analysis using the "Institute for Applied Health Research Berlin" (InGef) research database, containing claims data of approximately 4 million insured individuals. In the period from 2012-2017 all women born 1989-1992 were identified if they were continuously insured at an age between 23-25 years. Using ICD-10-GM codes (verified diagnosis in the outpatient sector or primary or secondary diagnosis in the inpatient sector) the administrative prevalence (95% confidence interval) of genital warts (A63.0), anogenital diseases grade I (K62.8, N87.0, N89.0, N90.0), grade II (N87.1, N89.1, N90.1) and grade III (D01.3, D06.-, D06.0, D07.1, D07.2, N87.2, N89.2, N90.2) was calculated.

Results

From 2012-2017, a total of 15,358 (birth cohort 1989), 16,027 (birth cohort 1990), 14,748 (birth cohort 1991) and 14,862 (birth cohort 1992) women at the age of 23-25 were identified. A decrease of the administrative prevalence was observed in genital warts (1.30% (1.12-1.49) birth cohort 1989 vs. 0.94% (0.79-1.10) birth cohort 1992) and anogenital diseases grade III (1.09% (0.93-1.26) birth cohort 1989 vs. 0.71% (0.58-0.86) birth cohort 1992). In anogenital diseases grade III, this trend was especially observed for severe cervical dysplasia (N87.2) (0.91% (0.76-1.07) birth cohort 1989 vs. 0.60% (0.48-0.74) birth cohort 1992). In contrast, anogenital diseases grade I (1.41% (1.23-1.61) birth cohort 1989 vs. 1.31% (1.14-1.51) birth cohort 1992) and grade II (0.61% (0.49-0.75) birth cohort 1989 vs. 0.52% (0.42-0.65) birth cohort 1992) remained stable.

Conclusions

A decrease of the burden of anogenital disease potentially related to HPV was observed in the younger birth cohorts. This trend was observed especially for genital warts and anogenital diseases grade III. Further research to investigate this trend for the upcoming years and for following birth cohorts is necessary also considering varying HPV vaccination coverage.

Background

Human papillomavirus (HPV) infection belongs to the most frequent sexually transmitted infections in men and women worldwide (1). Nearly all sexually active individuals will acquire at least one HPV infection in their life (2). Although the majority of HPV infections are cleared spontaneously within a couple of months, they may become persistent with a subsequently increased risk of developing certain cancer types and genital warts (3).

HPV types capable of infecting mucosal epithelia are subdivided into low-risk types and high-risk types. The low-risk types can lead to anogenital warts (condylomata acuminata), of these HPV types 6 and 11 are

responsible for approximately 90% of all anogenital warts cases (4). Genital warts are no life threatening condition, but they can cause psychological tension and embarrassment for the affected person (3). Currently available therapeutic interventions for warts do not guarantee a complete success. The recurrence rates range between 5%–65% (5). Worldwide, several million cases of anogenital warts occur each year in both sexes, with a peak incidence between 20 and 24 years of age for females and between 25 and 29 years among males (6). In Germany, crude incidence rate of anogenital warts for 10 to 79 year old women was reported with 181 per 100,000 person years in 2010 (7) .

High-risk HPV types can cause malignant conditions such as cervical intraepithelial neoplasia and cervical cancer (8), but also other anogenital precancerous lesions and cancers. Cervical cancer is the second most common cancer diagnosis as well as the third most frequent cause of cancer mortality among females in low-in-come countries (9). In Germany, about 4,600 women are newly diagnosed with cervical cancer every year and approximately 1,500 women die from cervical cancer per year (10). It is assumed that high-risk HPV infections cause practically all cervical cancers and precancers, approximately 90% of high-grade anal, vulvar and vaginal intraepithelial neoplasias, and approximately 30, 70, and 90% of vulvar, vaginal and anal cancers, respectively (11, 12). Of the at least 12 high-risk HPV types, HPV16 and 18 are responsible for 45% of cervical high-grade intraepithelial neoplasia and 70% of cervical cancers. Approximately 70–90% of HPV-associated precancers and cancers at non-cervical anogenital sites are induced by HPV16 and 18 (11).

Vaccination against HPV can prevent certain HPV infections and HPV related anogenital diseases. The European Medicines Agency (EMA) authorized the first HPV vaccines in 2006 (quadrivalent vaccine against HPV 6, 11, 16 and 18) and 2007 (bivalent HPV 16 and 18) (13). The quadrivalent vaccine protects against HPV types causing approximately 70% of cervical cancers and 90% of genital warts (3). Since 2016, the latest 9-valent vaccine is available in Germany which in addition to HPV types 6, 11, 16, and 18 also immunizes against the high-risk HPV types 31, 33, 45, 52, and 58 (14, 15). These five additional HPV types are supposed to account for 15–20% of all cervical carcinomas (16).

In 2007, the German Standing Committee on Vaccination (STIKO) released the first recommendation for HPV vaccination of girls in the age group 12–17 (17). In August 2014, the STIKO lowered the recommended vaccination age to 9–14 years. Since then, only two doses have been recommended. For catch-up vaccination at the age of 15–17 years, the STIKO continued to recommend three doses. Since the latest STIKO recommendation from 2018, HPV vaccination is recommended for girls and boys at the age of 9–14 with catch-up to the age of 17 (18). In the first year after the introduction of the HPV vaccination in Germany (2008), vaccination rate was reported with 32.2% for at least one dose in the target age group of the first STIKO recommendation (12- to 17-year-old girls) (19, 20). In 2015, HPV vaccination rate was 31.3% in 15 year old and 44.6% in 17 years old girls (3 doses) (21). Thus, in comparison to other countries with vaccination programs in schools, Germany has a lower immunization coverage for HPV (22). The burden of HPV related anogenital diseases has not been systematically evaluated for female birth cohorts eligible to receive the HPV vaccine after its introduction in 2007 in Germany.

The aim of this study was to assess the burden of anogenital diseases potentially related to HPV in women at the age of 23–25 based on diagnoses documented at German statutory health insurances (SHI). Included were women who were not eligible for HPV vaccination according to the first STIKO recommendation (birth cohort 1989) and women who were eligible for HPV vaccination according to STIKO recommendation (birth cohort

1990 to 1992). HPV vaccination status was not evaluated. Cervical cancer screening in Germany during the observation period was recommended for all women starting at an age of 20 with annual Pap tests. Thus, most diagnoses documented in claims data for the analyzed cohorts most likely result from screening attendance. It is an opportunistic screening without a general invitation system. Screening participation rate in women in their 20th was reported with approximately 60% annually and more than 70% bi-annually in 2011 (23).

Methods

Data Source

A retrospective claims database analysis was conducted using the "Institute for Applied Health Research Berlin" (InGef) research database. The database comprises anonymized healthcare claims data of approximately 8 million covered lives from about 60 different sickness funds. The data include patient demographics and characteristics, inpatient and outpatient diagnoses, surgeries and diagnostic codes, the healthcare resource utilization and costs of services for the inpatient care, outpatient care, pharmacological therapy, remedies, devices and aids, and sick leave in an anonymized case-by-case individual format. For scientific research projects, an adjusted analysis sample of the InGef database has been created which includes approximately 4 million covered lives structured to represent the German population in terms of age and gender according to the Federal Office of Statistics. The InGef sample represents about 5.5% of the German SHI population and 4.8% of the German population. It has been proven to have good external validity to the German population in terms of morbidity, mortality and drug use (24).

Study Population

This study included the first three female birth cohorts (1990, 1991, and 1992) which were eligible to receive vaccination against HPV according to the age recommended by STIKO in 2007. Furthermore, the last female birth cohort (1989) which was too old in 2007 to receive a HPV vaccination according to the STIKO recommendation was analyzed as a reference cohort. In total, the study population comprised all women in the InGef research database from 2012–2017 who were born in 1989, 1990, 1991, or 1992. All women had to be continuously observable from the age of 23 to 25, except for women who deceased. Age was determined at December 31st of each year.

HPV Related Anogenital Diseases

The identification of potentially HPV related anogenital diseases was based on International Statistical Classification of Diseases, German Modification (ICD–10-GM) codes. All potentially HPV related anogenital diseases (cytologically or histologically derived) in the outpatient sector (verified diagnoses) and in the inpatient sector (main and secondary diagnoses) were identified (*Table 1*).

Administrative Prevalence Rates (APR)

The 3-year APR for each female birth cohort and ICD−10-GM code were calculated by dividing the total number of women in the respective birth cohort with at least one of the defined ICD−10-GM codes by the total number of women in the respective birth cohort who were continuously observable in the observation period. The 3-year APR were reported in percent.

The 1-year APR for each age group in each female birth cohort and ICD−10-GM code were calculated by using a similar formula: total number of women in the respective birth cohort and age group with at least one of the defined ICD−10-GM codes divided by the total number of women in the respective birth cohort and age group who are each continuously observable in the respective calendar year. The 1-year APR were also reported in percent.

Furthermore, confidence intervals with 95% confidence level were calculated for APR by applying the exact Clopper−Pearson method, which is based on the exact binomial distribution and not a large sample normal approximation, as is the Wald method, and is rather suitable in case of a small n (25).

Results

The InGef research database included a total of 2,405,802 women from January 1st, 2012 to December 31st, 2017. In total, 16,027 to 14,748 women were continuously insured at the age of 23 to 25, including women who deceased in this age period. Within the three years of observation a minimum of five (birth cohort 1990) and a maximum of ten (birth cohort 1992) women deceased in the age period from 23 to 25 years (Figure 1).

The highest 3-year administrative APR in all birth cohorts was observed for anogenital diseases grade I (1.41% to 1.31% range), followed by genital warts (1.30% to 0.94% range) and anogenital diseases grade III (1.09% to 0.71% range). Anogenital diseases grade II (0.61% to 0.52% range) and especially invasive carcinoma (0.12% to 0.06% range) were less frequently documented (Figure 2).

- Genital Warts

The highest 3-year APR for genital warts was observed for birth cohort 1989 with 1.30% (1.12−1.49). A lower 3-year APR was observed for the younger cohorts (0.94% (0.79−1.10) birth cohort 1992) (all birth cohorts in Figure 2). The 1-year APR for genital warts are summarized for individual age years in the supplement (see ADDITIONAL FILE 1, Supplementary Figure 1).

- Anogenital Diseases Grade I

Three-year APR for anogenital diseases grade I remained stable (1.41% (1.23−1.61) in birth cohort 1989 to 1.31% (1.14−1.51) in birth cohort 1992). A peak was observed in birth cohort 1990 (1.60% (1.41−1.80). Among the anogenital diseases grade I mild cervical dysplasia (CIN I) was most frequently recorded, followed by other specified diseases of anus and rectum (AIN I & II). With a 3-year APR of maximum 0.12% for mild vaginal dysplasia (VAIN I) and 0.05% for mild vulvar dysplasia (VIN I) these two anogenital diseases were less frequently recorded compared with CIN I and AIN I & II. (Figure 3). 1-year APR for grade I disease are summarized for individual age years in the ADDITIONAL FILE 1, Supplementary Figure 2.

- Anogenital Diseases Grade II

Overall, the 3-year APR for anogenital diseases grade II remained stable over the four birth cohorts. It only decreased slightly from 0.61% (0.49−0.75) in birth cohort 1989 to 0.52% (0.42−0.65) in birth cohort 1992. Among the anogenital diseases grade II moderate cervical dysplasia (CIN II) was most frequently recorded. Moderate vaginal dysplasia (VAIN II) and moderate vulvar dysplasia (VIN II) were hardly recorded (Figure 4). 1-year APR for grade II disease are summarized for individual age years in the ADDITIONAL FILE 1, Supplementary Figure 3.

- Anogenital Diseases Grade III

The 3-year APR for anogenital diseases grade III was decreasing continuously from birth cohort 1989 (1.09% (0.93−1.26)) to birth cohort 1992 (0.71% (0.58−0,86)). Among the anogenital diseases grade III, severe cervical dysplasia was most frequently recorded and followed the trend of the pooled anogenital diseases grade III results. (Figure 5). 1-year APR for grade III disease are summarized for individual age years in the ADDITIONAL FILE 1, Supplementary Figure 4.

- Invasive carcinoma

The 3-year APR for invasive carcinomas ranged from 0.12% to 0.06% (0.07−0.19 in birth cohort 1989 and 0.03−0.11 in birth cohort 1992) (Figure 2). Malignant neoplasms of the cervix uteri were most frequently recorded and were responsible for almost all recorded diagnoses for carcinomas in all birth cohorts. Malignant neoplasms of anus and anal canal were not recorded at all in the analyzed birth cohorts.

Discussion

The aim of this study was to describe the burden of HPV-related anogenital diseases in 23−25 old women based on administrative claims data documented at German statutory health insurances (SHI). Data were obtained for the years 2012 to 2017. Included were birth cohorts 1990 to 1992, who were eligible to receive HPV vaccination according to the first STIKO recommendation in 2007, and birth cohort 1989, who exceeded the eligible age in 2007. HPV vaccination status of the study population was not evaluated.

In summary, the results demonstrate the highest APR among all analyzed birth cohorts for anogenital diseases grade I (1.41% in birth cohort 1989 to 1.31% in birth cohort 1992) followed by genital warts (1.30% in birth cohort 1989 to 0.94% in birth cohort 1991) and anogenital diseases grade III (1.09% in birth cohort 1989 to 0.71% in birth cohort 1992). For genital warts and grade III diseases a downward trend in the 3-year APR in favor of the younger birth cohorts was observed.

Germany has an opportunistic cervical cancer screening starting with age 20 and thus most documented diagnoses of intraepithelial neoplasia most likely have been identified during screening and further work-up (cytologically or histologically). Screening participation rate in women in their 20th was reported with approximately 60% annually and more than 70% bi-annually in 2011 (23).

The HPV vaccination status of the study population was unknown as the study period spanned from 2012 until 2017 and the study population should have received HPV vaccination between 2007 and 2009 according to the STIKO recommendation. For the analyzed birth cohorts two publications provide estimates on the HPV vaccination coverage. First, Hense et al. evaluated initiation of HPV vaccination in 2008 based on data from a

statutory health insurance and reported 37% of 16 years old girls with at least one dose, which would overlap with birth cohort 1992. In the same publication rates were 33%, 19% and 18% for 17-, 18-, and 19-year-old women, respectively (corresponding to birth cohorts 1992–1989) (20). Delere et al. reported HPV vaccination coverage based on self-reported history of approximately 2000 18–20 years old women in 2010 (cohorts 1990–1992) with 48.5% for three doses and 60.2% for at least one dose (26). While none of these figures most likely accurately represents the vaccination coverage of our study population in the analyzed time period, it might give three important estimates: 1) coverage rates for HPV vaccination in Germany were generally lower than in countries with vaccination programs in schools (22). In Australia e.g., the three-dose vaccination coverage for girls turning 15 years of age was 79% in 2015 (27). Hence, disease burden in birth cohorts eligible for HPV vaccination may still be higher than one might expect with a better vaccination coverage. 2) vaccination coverage increases from birth cohorts that were not eligible for HPV vaccination according to STIKO to birth cohorts that were eligible. Since we found a downward trend in the 3-year APR for selected diagnoses in favor of the younger birth cohorts, it may be speculated that this is due to increasing HPV vaccine coverage in younger cohorts. We found the downward trend in the 3-year APR for genital warts and grade III dysplasia, but not for grade I and II dysplasia. While this might be due to the rather low HPV vaccination coverage in Germany, it might be also correlated to the HPV types that are covered by the vaccines. HPV types causing the majority of genital warts (approximately 90% caused by HPV 6/11) and a number of grade III cervical diseases (approximately 45% caused by HPV 16/18) were covered by HPV vaccines available during the observation period (11). Grade I disease, however, are caused to a lesser extent by types 6, 11, 16 and 18 and hence, a vaccine effect might be masked in an analysis without selection for vaccine-HPV type-associated disease. And 3), also for birth cohort 1989, which was too old to be eligible for HPV vaccination according to STIKO recommendation, a coverage of approximately 18% was reported in 2008 (20). This birth cohort only turned 18 during the year 2007 and thus girls may have had the chance to receive the vaccination regularly before the birthday. Also, individual health insurances provided an extended reimbursement for HPV vaccination up to the age of 26 or the vaccine may have been purchased as self-payer. Hence, in none of the analyzed birth cohorts our prevalence rates for HPV diseases do reflect the situation in a population without HPV immunization.

The prevalence or incidence of HPV related anogenital diseases in Germany has only been systematically evaluated for selected diagnoses until now and not systematically for birth cohorts eligible to receive HPV vaccination. One previous German study examined HPV type prevalence (26) but has not investigated associated anogenital diseases. Further studies looking at the incidence of anogenital warts before and after the introduction of the HPV vaccination in German statutory health insurance members 10–79 years old reported the highest incidence of anogenital warts for the age group 20–24 years (4, 7, 28). In 2010, incidence was 493 per 100.000 person years in 20–24 years old and 149 per 100.000 person years in 15–19 years old females (7).

In a population-based surveillance study conducted from 2009–2010 in Wolfsburg/Germany to investigate the burden of HPV infections and associated anogenital diseases in women who were born in 1988 or 1989 (and 1983/84), an incidence of 0.72% and a total life risk of 1.4% for genital warts was estimated for the cohort 1988/89 (29). For the same cohort a prevalence of 0.83% for CIN II and 0.33% for CIN III diseases was detected (30). The 3-year APR for anogenital warts of 1.30% and for grade III cervical dysplasia of 0.60% for birth cohort 1989 found in our study generally fits into this dimension. In Australia an observational study based on clinical diagnoses reported a prevalence of genital warts of 18.4% in young women before the introduction of HPV

vaccination (31). The remarkably lower burden in our study might on the one hand be explained by the fact that our analyzes did not include a population in the pre-HPV-vaccine era, and on the other hand the use of administrative claims data in our study may have resulted in an underestimation of diagnoses (see further discussion on limitations below). It is also important to note that our analysis only provides a snapshot of the APR of anogenital diseases in women of a selected, young age (23–25). Genital warts are reported to have a peak incidence in the early twenties and occur also in even younger women (4) and thus the analyzed age groups might resemble a high prevalence group. In contrast, data from the German Centre for Cancer Registry Data (ZfKD) from 2014 show the highest burden for invasive anogenital diseases in women between 45–54 years (14.5 per 100,000) for cervical cancer and women 75 years and older for vulvar cancer (22.7 per 100,000) (32). Therefore, our results may not be transferable to the prevalence rates of HPV related anogenital diseases over the complete lifetime.

Epidemiology data on vulvar and vaginal cancer and precancer is rather scarce for Germany especially for younger age groups. Even though an increased incidence of VIN grades since the mid−1970s and especially among women at the age between 35 and 40, end of the 1990s the incidence rate was at 7 cases per 100,000 women (33). The incidence of vulvar and vaginal cancer is, however, still increasing with age where the peak incidence is expected between 60 and 74 years (33). In our study we found only very few patients (n = 0-<5 patients per birth cohort). As our study population included only patients at the age of 23–25 this low APR was expected.

Single previous reports focused on HPV vaccine impact in Germany. Deleré et al. found a significant lower HPV 16/18 prevalence in vaccinated women suggesting first effects of the vaccination. Data from the German Pharmacoepidemiological Research Database (GePaRD) also, demonstrated a decline of anogenital warts among males and females at the age of 14−24 comparing the timeframe prior to vaccination with the timeframe after vaccination. While the largest decrease (by 60%) was observed for women in the age group 16–20, the incidence ratio in women aged between 21−26 years was reduced by 10−20% (7). In our study genital warts have been reduced by 28% (from 1.30% in birth cohort 1989 to 0.94% in birth cohort 1992), and HPV related anogenital diseases grade III have been reduced by 35% (from 1.09% in birth cohort 1989 to 0.71 in birth cohort 1992). A systematic review assessing the global effect of HPV vaccination revealed reductions of approximately 90% for genital warts, approximately 45% for low-grade cytological cervical abnormalities, and approximately 85% for high-grade histologically proven cervical abnormalities (34). Another international systematic review assessing the early direct and indirect impact of the quadrivalent HPV vaccine on genital warts also found a 92.6% reduction in the incidence of anogenital warts for all women <21 years, where the vaccine uptake rate was 70% for 3 doses (35).

The present study has several additional limitations, most inherent with the use of health insurance claims data. Claims data are primarily collected for reimbursement purposes. Therefore, only patients who see a physician and cause reimbursement for the health insurance could be identified in the database. Patients without symptoms might not seek medical advice, individuals that do not participate in screening examinations might not be identified, and patients who treat their disease (e.g. genital warts) by themselves or ignore the condition are not recorded in the database. Therefore, this study only presents the administrative prevalence based on reimbursement data and not the clinical prevalence of potentially HPV related anogenital diseases on population level.

For the identification of potentially HPV related anogenital diseases we used ICD–10-GM codes, which is the official classification for the encoding of diagnoses in inpatient and outpatient medical care in Germany since 2000 (36). Clinicians in the outpatient setting are required to add one of the following specifications to the ICD–10-GM codes: "suspected diagnosis", "diagnosis ruled out", "condition after the respective diagnosis", or "verified diagnosis". For instance, "suspected" may be coded, if the physician is not certain about the presence of the coded disease and a confirming laboratory analysis is still pending. To ensure the accuracy of diagnoses only verified diagnoses in the outpatient and primary and secondary diagnoses in the inpatient sector were used. With this approach however, we excluded women who might be suspected to have one of the investigated anogenital diseases or women who have been cured from of the anogenital diseases (e.g. genital warts) and see their physician for a follow-up visit. This could have led to an underestimation of the APR. Additionally, we decided to only consider very specific ICD–10-GM codes potentially associated with HPV-associated anogenital diseases, but physicians may use less specific codes. This might also have contributed to underestimation of the true rate of clinical diagnoses.

Cervical cancer screening in Germany is Pap-based for women in their 20th and most documented diagnoses in our analysis most likely are cytologically or histologically defined. No laboratory data was used additionally for this study to demonstrate an HPV association of anogenital diseases. Therefore, it is not possible to distinguish between anogenital diseases, which are caused by an HPV infection and those which are not caused by an HPV infection. However, it is expected that high-risk HPV infections cause practically all cervical cancers and precancers, approximately 90% of high-grade anal, vulvar and vaginal intraepithelial neoplasia and 30, 70 and 90% of vulvar, vaginal and anal cancers, respectively (11) and therefore, a very high rate of HPV-association is expected for our captured diagnoses.

Conclusions

In summary, our results demonstrate the highest administrative prevalence for anogenital diseases grade I, followed by genital warts and anogenital diseases grade III among all analyzed birth cohorts. Even though the HPV vaccination status of the study population was unknown, a decrease of the disease burden of genital warts and anogenital grade III disease was observed in favor of the younger birth cohorts who were eligible for HPV vaccination according to STIKO recommendation. Further research is necessary to confirm the observed trend including analyses linked to vaccination status.

List Of Abbreviations

AIN Anal intraepithelial neoplasia

APR Administrative prevalence rate

CIN Cervical intraepithelial neoplasia

CIS Carcinoma in situ

EMA European Medicines Agency

GePaRD German Pharmacoepidemiological Research Database

HPV Human papillomavirus

ICD–10-GM International Statistical Classification of Diseases, German Modification

InGef Institute for Applied Health Research Berlin [Institut für Angewandte Gesundheitsforschung Berlin]

OTC Over-the-counter

SHI Statutory health insurance [Gesetzliche Krankenversicherung]

STIKO German Standing Committee on Vaccination [Ständige Impfkomission]

VAIN Vaginal intraepithelial neoplasia

VIN Vulvar intraepithelial neoplasia

ZfKD German Centre for Cancer Registry Data [Zentrum für Krebsregister Daten]

Declarations

Ethics approval and consent to participate

This study used anonymized German claims data. Therefore, no ethics approval was needed by an independent ethics committee or institutional review board. The utilized database addresses all data protection regulations in Germany. To ensure the protection of individual data and privacy, regions that are smaller than federal states or patient cohorts with less than 100 individuals were not analyzed in a granular way. Furthermore, patient counts below 5 were reported as "<5".

Consent for publication

Not applicable.

Availability of data and materials

The utilized database in this study is available from the Institute for Applied Health Research Berlin (InGef) but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available.

Competing interests

MR, SM, and RW are full time employees of MSD SHARP & DOHME GmbH. KS, CJ, and SB are full-time employees of Xcenda, acting as contractors of MSD SHARP & DOHME GmbH for the execution of this study. MH received honoraria as speaker and member of medical advisory boards from MSD Sharp & Dohme GmbH, Astra Zeneca, Gedeon Richter and honoraria as an author for Thieme and Springer.

Funding

This study was funded by MSD SHARP & DOHME GmbH.

Authors' contributions

MR, SM, RW, KS, CJ, and MH developed the study design. KS, and CJ analyzed the dataset and drafted the manuscript. MR, SM, RW, KS, CJ and MH interpreted the data and contributed to the development of the manuscript. All authors provided critical review and revision of drafts, and approval of the final manuscript.

Acknowledgements

The analyses were performed in collaboration with Prof. Dr. Wolfgang Greiner and the Institute for Applied Health Research Berlin (InGef).

References

1.Lyu Z, Feng X, Li N, Zhao W, Wei L, Chen Y, et al. Human papillomavirus in semen and the risk for male infertility: a systematic review and meta-analysis. BMC infectious diseases. 2017;17(1):714.

2.World Health Organization (WHO). Human papillomavirus (HPV) and cervical cancer: World Health Organization (WHO),; 2019 [updated 2019/01/24. Available from: https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer.

3.Braaten KP, Laufer MR. Human Papillomavirus (HPV), HPV-Related Disease, and the HPV Vaccine. Rev Obstet Gynecol. 2008;1(1):2–10.

4.Kraut AA, Schink T, Schulze-Rath R, Mikolajczyk RT, Garbe E. Incidence of anogenital warts in Germany: a population-based cohort study. BMC infectious diseases. 2010;10:360.

5.Kodner CM, Nasraty S. Management of genital warts. Am Fam Physician. 2004;70(12):2335–42.

6.Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC infectious diseases. 2013;13:39-.

7.Thöne K, Horn J, Mikolajczyk R. Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine-an interrupted time series analysis from 2005 to 2010 using health insurance data. BMC infectious diseases. 2017;17(1):564-.

8.Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244–65.

9.Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.

10.Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland. Krebs in Deutschland für 2013/2014. Berlin: Robert Koch-Institut; 2017.

11.Hartwig S, Baldauf J-J, Dominiak-Felden G, Simondon F, Alemany L, de Sanjosé S, et al. Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines. Papillomavirus Research. 2015;1:90–100.

12.Reuschenbach M, Roos J, Panayotopoulos D, Baldus SE, Schnürch H-G, Berger A, et al. Characterization of Squamous Cell Cancers of the Vulvar Anterior Fourchette by Human Papillomavirus, p16INK4a, and p53. Journal of Lower Genital Tract Disease. 2013;17(3):289–97.

13.European Medicines Agency. HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS London, United Kingdom2016 [Available from: https://www.ema.europa.eu/en/documents/referral/hpv-vaccines-article–20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-pots_en.pdf.

14.Robert Koch-Institut. Impfquoten bei der Schuleingangsuntersuchung in Deutschland 2014. Epidemiologisches Bulletin,. 2016;16/2014:129–42.

15.Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–23.

16.Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012;7(1):38.

17.Robert Koch-Institut. Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Impfung gegen humane Papillomaviren (HPV) für Mädchen von 12 bis 17 Jahren—Empfehlung und Begründung. Epidemiologisches Bulletin. 2007;12/2007:97–106.

18.Takla A, Wiese-Posselt M, Harder T, Meerpohl JJ, Röbl-Mathieu M, Terhardt M, et al. Background paper for the recommendation of HPV vaccination for boys in Germany. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2018;61(9):1170–86.

19.Robert Koch-Institut. Wissenschaftliche Begründung für die Empfehlung der HPV-Impfung für Jungen im Alter von 9 bis 14 Jahren. Epidemiologisches Bulletin,. 2018;26/2018:233–54.

20.Hense S, Hillebrand K, Horn J, Mikolajczyk R, Schulze-Rath R, Garbe E. HPV vaccine uptake after introduction of the vaccine in Germany: an analysis of administrative data. Hum Vaccin Immunother. 2014;10(6):1729–33.

21.Robert Koch-Institut. Aktuelles aus der KV-Impfsurveillance—Impfquoten ausgewählter Schutzimpfungen in Deutschland. Epidemiologisches Bulletin. 2018;1/2018.

22.Robert Koch-Institut. Vaccination againsthuman papillomavirus (HPV) in girls. Fact sheet on KiGGS Wave 1: German Health Interview and Examination Survey for Children and Adolescents—First follow-up interview 2009–2012. 2014.

23.Geyer S, Jaunzeme J, Hillemanns P. Cervical cancer screening in Germany: group-specific participation rates in the state of Niedersachsen (Lower Saxony). A study with health insurance data. Archives of gynecology and obstetrics. 2015;291(3):623–9.

24.Andersohn F, Walker J. Characteristics and external validity of the German Health Risk Institute (HRI) Database. Pharmacoepidemiology and drug safety. 2016;25(1):106–9.

25.Agresti A, Coull BA. Approximate Is Better than "Exact" for Interval Estimation of Binomial Proportions. The American Statistician. 1998;52(2):119–26.

26.Delere Y, Remschmidt C, Leuschner J, Schuster M, Fesenfeld M, Schneider A, et al. Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling. BMC infectious diseases. 2014;14:87.

27.National HPV Vaccination Program Register. National (Australia) HPV 3 dose vaccination coverage for females turning 15 years of age in 2015 2018 [Available from: http://www.hpvregister.org.au/site/DefaultSite/filesystem/documents/Coverage-Data/2018/Coverage%20by%20dose%202015%20-%20females.pdf.

28.Mikolajczyk RT, Kraut AA, Horn J, Schulze-Rath R, Garbe E. Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany-an ecologic study. Sexually transmitted diseases. 2013;40(1):28–31.

29.Petry KU, Luyten A, Justus A, Iftner A, Strehlke S, Schulze-Rath R, et al. Prevalence of low-risk HPV types and genital warts in women born 1988/89 or 1983/84 - results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC infectious diseases. 2012;12:367.

30.Petry KU, Luyten A, Justus A, Iftner A, Strehlke S, Reinecke-Luthge A, et al. Prevalence of high-risk HPV types and associated genital diseases in women born in 1988/89 or 1983/84 - results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC infectious diseases. 2013;13:135.

31.Chow EPF, Read TRH, Wigan R, Donovan B, Chen MY, Bradshaw CS, et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sexually Transmitted Infections. 2015;91(3):214–9.

32.Zentrum für Krebsregisterdaten (ZfKD). Datenbankabfrage 2017 [Available from: https://www.krebsdaten.de/Krebs/SiteGlobals/Forms/Datenbankabfrage/datenbankabfrage_stufe2_form.html.

33.Dittmer C, Katalinic A, Mundhenke C, Thill M, Fischer D. Epidemiology of vulvar and vaginal cancer in Germany. Archives of gynecology and obstetrics. 2011;284(1):169–74.

34.Garland SM, Kjaer SK, Munoz N, Block SL, Brown DR, DiNubile MJ, et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2016;63(4):519–27.

35.Mariani L, Vici P, Suligoi B, Checcucci-Lisi G, Drury R. Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review. Advances in therapy. 2015;32(1):10−30.

36.Deutsches Institut für Medizinische Dokumentation und Information (DIMDI). ICD−10-GM - Versionsverlauf und Bekanntmachungen: Deutsches Institut für Medizinische Dokumentation und Information; 2019 [Available from: https://www.dimdi.de/dynamic/de/klassifikationen/icd/icd−10-gm/historie/versionsverlauf/.

Tables

Table 1 List of ICD-10-GM codes utilized for identification of potentially HPV related anogenital diseases

Group	Description	ICD-10-GM Code
Genital warts	Anogenital (venereal) warts (condylomata)	A63.0
Grade I	Other specified diseases of anus and rectum (AIN I & II)	K62.8
	Mild cervical dysplasia (CIN I)	N87.0
	Mild vaginal dysplasia (VAIN I)	N89.0
	Mild vulvar dysplasia (VIN I)	N90.0
Grade II	Moderate cervical dysplasia (CIN II)	N87.1
	Moderate vaginal dysplasia (VAIN II)	N89.1
	Moderate vulvar dysplasia (VIN II)	N90.1
Grade III	Carcinoma in situ of anus and anal canal (AIN III)	D01.3
	Carcinoma in situ of cervix uteri (CIN III)	D06.-
	Carcinoma in situ of endocervix	D06.0
	Carcinoma in situ of vulva (VIN III)	D07.1
	Carcinoma in situ of vagina (VAIN III)	D07.2
	Severe cervical dysplasia	N87.2
	Severe vaginal dysplasia, other	N89.2
	Severe vulvar dysplasia, other	N90.2
Carcinoma	Malignant neoplasm of cervix uteri	C53.-
	Malignant neoplasm of anus and anal canal	C21.-
	Malignant neoplasm of vulva	C51.-
	Malignant neoplasm of vagina	C52.-

Figures

Figure 1

Patient flowchart * Including patients who deceased in the respective observation period/year

Figure 2

Three-year APR of anogenital diseases in women 23-25 years in Germany from 2012-2017 APR=Administrative prevalence rate

Figure 3

Three-year APR of anogenital diseases grade I in 23-25-year-old women in Germany from 2012-2017 APR=Administrative prevalence rate; AIN=anal intraepithelial neoplasia; CIN=cervical intraepithelial neoplasia; VAIN=vaginal intraepithelial neoplasia; VIN=vulvar intraepithelial neoplasia. Due to data protection regulations results for patients with n<5 must not be reported and can constitute 1 to 4 patients.

Figure 4

Three-year APR of anogenital diseases grade II in 23-25-year-old women in Germany from 2012-2017
APR=Administrative prevalence rate; AIN=anal intraepithelial neoplasia; CIN=cervical intraepithelial neoplasia; VAIN=vaginal intraepithelial neoplasia; VIN=vulvar intraepithelial neoplasia. Due to data protection regulations results for patients with n<5 must not be reported and can constitute 1 to 4 patients.

Figure 5

Three-year APR of anogenital diseases grade III in 23-25-year-old women in Germany from 2012-2017 APR=Administrative prevalence rate, CIS=Carcinoma in situ, AIN=anal intraepithelial neoplasia; CIN=cervical intraepithelial neoplasia; VAIN=vaginal intraepithelial neoplasia; VIN=vulvar intraepithelial neoplasia. AIN III, VIN III, VAIN III, and other severe vaginal and vulvar dysplasia has been excluded from this figure as patient counts were either n=0 or n<5. Due to data protection regulations results for patients with n<5 must not be reported and can constitute 1 to 4 patients.